Workflow
ZHONGZHU HEALTHCARE HOLDING(600568)
icon
Search documents
ST中珠:股东郑子贤所持500万股股份解除冻结
Mei Ri Jing Ji Xin Wen· 2025-08-11 09:14
ST中珠(SH 600568,收盘价:1.79元)8月11日晚间发布公告称,日前通过中国证券登记结算有限责任 公司上海分公司系统查询获悉,公司股东郑子贤女士被冻结的500万股股份已解除冻结。本次股份解除 冻结后,郑子贤女士所持公司股份累计被冻结数量为0股。 (文章来源:每日经济新闻) 2024年1至12月份,ST中珠的营业收入构成为:医院收入占比55.6%,房地产项目占比25.33%,医药行 业占比8.94%,医疗器械占比4.74%,中心合作占比4.17%。 ...
ST中珠:张卫滨辞去公司副总裁、董事会秘书等职务
Mei Ri Jing Ji Xin Wen· 2025-08-11 09:14
Core Viewpoint - ST Zhongzhu announced the resignation of Vice President and Board Secretary Zhang Weibin due to personal reasons, effective immediately, and he will no longer hold any positions within the company [2] Financial Performance - For the year 2024, ST Zhongzhu's revenue composition is as follows: hospital income accounts for 55.6%, real estate projects 25.33%, pharmaceutical industry 8.94%, medical devices 4.74%, and center cooperation 4.17% [2]
ST中珠: 中珠医疗控股股份有限公司关于公司副总裁兼董事会秘书离任的公告
Zheng Quan Zhi Xing· 2025-08-11 09:13
证券代码:600568 证券简称:ST 中珠 公告编号:2025-030 号 中珠医疗控股股份有限公司 关于公司副总裁兼董事会秘书离任的公告 中珠医疗控股股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 二〇二五年八月十二日 中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公司")董事会于 滨先生因个人原因辞去公司副总裁、董事会秘书、公司内部及下属公司职务,辞 职后不再担任公司任何职务。 根据《上海证券交易所股票上市规则》的有关规定,在公司董事会秘书空缺 期间,暂由董事长陈旭先生代行董事会秘书职责,相关工作已完成交接。公司将 按照法定程序尽快完成董事会秘书的聘任工作。 截至本公告日,张卫滨先生未持有公司股份,不存在应当履行而未履行的公 开承诺事项。 公司及董事会对张卫滨先生任职期间为公司所做出的贡献表示衷心的感谢。 特此公告。 一、提前离任的基本情况 | | | | | | | | 是否继续在上 | 是否存在未 | | | --- | --- | --- | --- | --- | --- ...
ST中珠: 中珠医疗控股股份有限公司关于公司高级管理人员离任的公告
Zheng Quan Zhi Xing· 2025-08-11 09:13
一、高级管理人员离任情况 证券代码:600568 证券简称:ST 中珠 公告编号:2025-031 号 中珠医疗控股股份有限公司 关于公司高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公司")董事会于 原因辞去公司副总裁职务,辞职后不再担任公司任何职务。 公司任职 公开承诺 曾钰成 副总裁 个人原因 否 否 (二) 离任对公司的影响 根据《中华人民共和国公司法》及《公司章程》的规定,曾钰成先生上述辞 职事项自书面辞职报告送达董事会之日起生效,公司已做好相关工作安排,曾钰 成先生离任不会影响公司的正常生产经营。 截至本公告日,曾钰成先生未持有公司股份,不存在应当履行而未履行的公 开承诺事项。 本公司及董事会对曾钰成先生在任职期间为公司发展所做出的贡献表示衷 心的感谢。 (一) 提前离任的基本情况 是否继续在上市 是否存在未 原定任期到 毕的 姓名 离任职务 离任时间 离任原因 公司及其控股子 履行完 期日 特此公告。 中珠医疗控股股份有限 ...
ST中珠:副总裁曾钰成离任
Mei Ri Jing Ji Xin Wen· 2025-08-11 08:50
(文章来源:每日经济新闻) ST中珠(SH 600568,收盘价:1.79元)8月11日晚间发布公告称,中珠医疗控股股份有限公司董事会于 2025年8月11日收到公司副总裁曾钰成先生的书面辞职报告。曾钰成先生因个人原因辞去公司副总裁职 务,辞职后不再担任公司任何职务。 2024年1至12月份,ST中珠的营业收入构成为:医院收入占比55.6%,房地产项目占比25.33%,医药行 业占比8.94%,医疗器械占比4.74%,中心合作占比4.17%。 ...
ST中珠(600568) - 中珠医疗控股股份有限公司关于公司副总裁兼董事会秘书离任的公告
2025-08-11 08:45
证券代码:600568 证券简称:ST 中珠 公告编号:2025-030 号 中珠医疗控股股份有限公司 关于公司副总裁兼董事会秘书离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公司")董事会于 2025年8月11日收到公司副总裁兼董事会秘书张卫滨先生的书面辞职报告。张卫 滨先生因个人原因辞去公司副总裁、董事会秘书、公司内部及下属公司职务,辞 职后不再担任公司任何职务。 一、提前离任的基本情况 二、离任对公司的影响 根据《上海证券交易所股票上市规则》的有关规定,在公司董事会秘书空缺 期间,暂由董事长陈旭先生代行董事会秘书职责,相关工作已完成交接。公司将 按照法定程序尽快完成董事会秘书的聘任工作。 截至本公告日,张卫滨先生未持有公司股份,不存在应当履行而未履行的公 开承诺事项。 公司及董事会对张卫滨先生任职期间为公司所做出的贡献表示衷心的感谢。 特此公告。 中珠医疗控股股份有限公司董事会 二〇二五年八月十二日 | 姓名 | 离任职务 | 离任时间 | ...
ST中珠(600568) - 中珠医疗控股股份有限公司关于公司高级管理人员离任的公告
2025-08-11 08:45
证券代码:600568 证券简称:ST 中珠 公告编号:2025-031 号 中珠医疗控股股份有限公司 关于公司高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公司")董事会于 2025年8月11日收到公司副总裁曾钰成先生的书面辞职报告。曾钰成先生因个人 原因辞去公司副总裁职务,辞职后不再担任公司任何职务。 一、高级管理人员离任情况 (一) 提前离任的基本情况 | 姓名 | 离任职务 | 离任时间 | 原定任期到 | | 离任原因 | 是否继续在上市 公司及其控股子 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 期日 | | | | 履行完毕的 | | | | | | | | 公司任职 | 公开承诺 | | | 副总裁 | 2025 年 8 月 | 2027 年 | 12 月 | | | | | 曾钰成 | | | | | 个人原因 | 否 | 否 ...
ST中珠(600568) - 中珠医疗控股股份有限公司关于公司股东所持部分股份解除冻结的公告
2025-08-11 08:45
郑子贤女士本次解除冻结股份数量为 5,000,000 股,占其持有公司股份总数的 5.00%,占公司总股本的 0.25%。 本次股份解除冻结后,郑子贤女士所持公司股份累计被冻结数量为 0 股。 证券代码:600568 证券简称:ST 中珠 公告编号:2025-032 号 中珠医疗控股股份有限公司 关于公司股东所持部分股份解除冻结的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截止本公告披露日,中珠医疗控股股份有限公司(以下简称"中珠医疗"或"公 司")股东郑子贤女士持有公司无限售流通股 100,000,000 股,占公司总股本 5.02%。 一、本次解除冻结股份原被冻结的基本情况 2025 年 5 月 23 日,公司披露《中珠医疗控股股份有限公司关于公司股东所持部分 股份被司法冻结的公告》(公告编号:2025-027 号)。因公司股东郑子贤女士与汉德产业 投资基金管理有限公司财产保全一案,郑州高新技术产业开发区人民法院对郑子贤女士 持有公司 5,000,000 股股份实施冻,占其持有公司股份总 ...
电力行业财务总监CFO观察:三博士均高薪 国投电力周长信147万元 长江电力詹平原110万元 华电新能吴豪75万元
Xin Lang Zheng Quan· 2025-08-11 02:39
Summary of Key Points Core Viewpoint - The 2024 A-share CFO data report reveals significant insights into the compensation structure and performance of CFOs in listed companies, highlighting discrepancies between salary increases and company performance. Group 1: Compensation Overview - The total compensation for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - The average salary for CFOs in the public utility-electricity sector is approximately 743,800 yuan, with the highest salary being 1.90 million yuan and the lowest at 202,900 yuan [1] - The majority of CFOs (61%) earn between 500,000 and 1 million yuan [1] Group 2: Age Structure - The average age of CFOs is approximately 49.58 years, with the most common age group being 40-49 years, comprising 39% of the total [3] - The oldest CFOs are 57 years old, while the youngest is 32 years old, with respective salaries of 742,200 yuan and 600,500 yuan [3] Group 3: Educational Background - The distribution of educational qualifications among CFOs includes 3 PhDs, 19 Master's degrees, 30 Bachelor's degrees, and 5 Associate degrees, with corresponding average salaries of 1.11 million yuan, 860,200 yuan, 683,000 yuan, and 532,700 yuan [5] - There is a positive correlation between education level and salary, with companies employing PhDs having market values exceeding 100 billion yuan [5] Group 4: Performance and Compensation Relationship - There are instances of salary increases for CFOs despite declines in company performance, such as a 107% salary increase for a CFO while the company's net profit dropped significantly [7] - Five CFOs received warnings or public notifications regarding compliance issues in 2024-2025 [7] Group 5: Compliance Issues - Specific CFOs faced multiple warnings for various compliance issues, including improper revenue recognition and delayed performance disclosures, impacting their companies' financial reporting [8][9][10] - For example, a CFO received four warnings related to improper financial practices, leading to significant misstatements in reported revenues and profits [8]
中珠医疗(600568) - 2025 Q2 - 季度业绩预告
2025-07-14 09:35
[Current Period Performance Forecast](index=1&type=section&id=Item%20I.%20Current%20Period%20Performance%20Forecast) The company forecasts a net loss for H1 2025, with attributable net profit between -20 million and -28 million RMB and non-recurring adjusted net profit between -26 million and -34 million RMB 2025 Half-Year Performance Forecast | Indicator | Estimated Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | -20 million to -28 million | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | -26 million to -34 million | - This performance forecast is unaudited by a certified public accountant[5](index=5&type=chunk) [Operating Performance and Financial Status in the Same Period Last Year](index=1&type=section&id=Item%20II.%20Operating%20Performance%20and%20Financial%20Status%20in%20the%20Same%20Period%20Last%20Year) Compared to the prior year, the company's anticipated loss for H1 2025 has narrowed, with H1 2024 net profit attributable to shareholders at -65.3011 million RMB and non-recurring adjusted net profit at -68.2797 million RMB 2024 Half-Year Performance (Prior Period) | Indicator | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Shareholders | -65.3011 million | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | -68.2797 million | | Earnings Per Share | -0.033 | [Primary Reasons for Current Period's Anticipated Loss](index=1&type=section&id=Item%20III.%20Primary%20Reasons%20for%20Current%20Period%27s%20Anticipated%20Loss) The anticipated loss primarily stems from core business challenges, including operating losses in the real estate sector due to low prices and losses from Beijing Zhongcheng Oncology Hospital's fixed expenses without revenue, partially offset by a non-recurring bankruptcy claim distribution [Impact of Core Business](index=1&type=section&id=Item%20III.%20%28I%29%20Impact%20of%20Core%20Business) Core business losses primarily arise from the real estate segment due to low market prices and Beijing Zhongcheng Oncology Hospital's fixed expenses without revenue - The real estate segment incurred operating losses due to depressed market prices[7](index=7&type=chunk) - Beijing Zhongcheng Oncology Hospital incurred losses due to fixed expenses and costs without generating revenue[9](index=9&type=chunk) [Impact of Non-Recurring Items](index=2&type=section&id=Item%20III.%20%28II%29%20Impact%20of%20Non-Recurring%20Items) The company received a bankruptcy claim distribution from the administrator of Shenzhen Yiti Investment Holding Group Co., Ltd., recognized as a non-recurring gain - A bankruptcy claim distribution from the administrator of Shenzhen Yiti Investment Holding Group Co., Ltd. was received this period, classified as a non-recurring item[9](index=9&type=chunk) [Risk Warning](index=2&type=section&id=Item%20IV.%20Risk%20Warning) The company emphasizes that this performance forecast is a preliminary, unaudited estimate by its finance department, and final results may differ - This performance forecast represents preliminary calculations by the company's finance department and has not been audited by a certified public accountant[10](index=10&type=chunk) [Other Explanatory Matters](index=2&type=section&id=Item%20V.%20Other%20Explanatory%20Matters) The company states that detailed performance data will be disclosed in the 2025 half-year report, advising investors to rely on official information from designated media and the Shanghai Stock Exchange website for investment decisions - Final detailed performance data will be disclosed in the company's 2025 half-year report[11](index=11&type=chunk) - The company's designated information disclosure media include Shanghai Securities News, China Securities Journal, Securities Times, Securities Daily, and the Shanghai Stock Exchange website[11](index=11&type=chunk)